Lightlake Therapeutics Inc.’ Binge Eating Disorder Treatment Phase II Trial Results Presented at American Psychiatric Association 2013 Annual Meeting

Published: May 23, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

LONDON--(BUSINESS WIRE)--Lightlake Therapeutics Inc. (OTCBB: LLTP) (the “Company”, “We” or “Lightlake”), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that results of the Company’s Phase II clinical trial of its nasal spray treatment for Binge Eating Disorder (“BED”) were presented at the American Psychiatric Association (“APA”) Annual Meeting in San Francisco by Professor Hannu Alho, MD, professor of addiction medicine at the University of Helsinki and Principal Investigator for the trial.

Help employers find you! Check out all the jobs and post your resume.

Back to news